LYEL - Lyell Immunopharma Inc
21.49
-1.130 -5.258%
Share volume: 63,263
Last Updated: 04-28-2026
Pharmaceutical Products/Pharmaceutical Preparations:
-0.12%
PREVIOUS CLOSE
CHG
CHG%
$22.62
-1.13
-0.05%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-06-2024 | 08-07-2024 | 11-07-2024 | 03-11-2025 | 05-13-2025 | 11-12-2025 | 03-12-2026 | |
| Assets | ||||||||
| Total Assets | 694.220 M | 654.142 M | 619.215 M | 490.859 M | 429.798 M | 407.965 M | 340.052 M | |
| Current Assets | 534.165 M | 499.824 M | 450.045 M | 379.594 M | 309.178 M | 328.201 M | 260.939 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 400.650 M | 357.695 M | 340.248 M | 264.930 M | 180.849 M | 196.049 M | 187.039 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 125.650 M | 133.424 M | 100.299 M | 105.597 M | 120.328 M | 123.575 M | 60.181 M | |
| Total Non-current Assets | 19.000 M | 19.000 M | 39.112 M | 32.014 M | 47.949 M | 19.000 M | 19.000 M | |
| Property Plant Equipment | 97.836 M | 93.096 M | 88.047 M | 48.200 M | 44.195 M | 36.722 M | 34.771 M | |
| Other Assets | 62.219 M | 61.222 M | 81.123 M | 63.065 M | 76.425 M | 43.042 M | 44.342 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 694.220 M | 654.142 M | 619.215 M | 490.859 M | 429.798 M | 407.965 M | 340.052 M | |
| Total liabilities | 91.063 M | 87.641 M | 88.518 M | 108.035 M | 93.277 M | 78.844 M | 91.850 M | |
| Total current liabilities | 32.353 M | 30.879 M | 33.512 M | 53.788 M | 41.285 M | 31.878 M | 49.412 M | |
| Accounts Payable | 4.895 M | 4.199 M | 3.596 M | 5.366 M | 3.728 M | 2.568 M | 2.893 M | |
| Other liabilities | 58.710 M | 56.762 M | 55.006 M | 54.247 M | 51.992 M | 46.966 M | 42.438 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 58.710 M | 56.762 M | 55.006 M | 54.247 M | 51.992 M | 46.966 M | 42.438 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 603.157 M | 566.501 M | 530.697 M | 382.824 M | 336.521 M | 329.121 M | 248.202 M | |
| Common stock | 1.666 B | 1.675 B | 1.683 B | 1.728 B | 1.734 B | 1.808 B | 1.868 B | |
| Retained earnings | -1.063 B | -1.109 B | -1.153 B | -1.345 B | -1.397 B | -1.479 B | -1.620 B |